APOE genotyping and response to drug treatment in Alzheimer's disease [1]

Lancet

Volumn 349, Issue 9051, 1997, Pages 539-

  Richard, Florence ^b   Helbecque, Nicole ^b   Neuman, Eric ^b   Guez, David ^b   Levy, Raymond ^b   Amouyel, Philippe ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 8 (2 MORPHOLINYLMETHOXY) 1,2,3,4 TETRAHYDROQUINOLINEMETHANE SULFONATE; 1,2,3,4 TETRAHYDRO 1 METHYL 8 (2 MORPHOLINYLMETHOXY)QUINOLINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ATTENTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE FREQUENCY; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MEMORY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0342618423     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)80089-X     Document Type: Article

References (5)

1. Van Gool WA, van Crevel H. Impact on management of new diagnostic tests in Alzheimer's disease. Lancet 1996; 348: 961.
2. National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996; 347: 1091-95.
3. Guez D, Neuman E, Malbezin M. Pharmacodynamic and early clinical studies with S12024 in Alzheimer's disease. In: Levy R, Howard R, eds. Developments in dementia and functional disorders in the elderly. Petersfield, UK and Bristol, USA: Wrightson Biomedical Publishing Ltd, 1995: 69-75.
4. Allain H, Neuman E, Malbezin M, et al. Bridging study of S12024 in 53 in-patients with Alzheimer's disease. J Am Geriatr Soc 1996; 45: 125-26.
5. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 1995; 92: 12260-64.